Recent Press Releases

Bayer significantly improves earnings

Very good business development at HealthCare / CropScience performance steady in a weaker market environment / MaterialScience posts robust earnings growth / Group sales increase to EUR 12,090...

Merck Announces Second-Quarter 2015 Financial Results

Second-Quarter 2015 Non-GAAP EPS of $0.86, Excluding Certain Items; GAAP EPS of $0.24 Company Narrows and Raises 2015 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items;...

Hikma acquires Roxane Laboratories, transforming its position in the US generics market

Hikma acquires Roxane Laboratories, transforming its position in the US generics market Acquisition enhances scale and will create platform for sustainable long-term growth Expected to be accretive...

Amgen Announces Webcast of 2015 Second Quarter Financial Results

THOUSAND OAKS, Calif., July 27, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will re

Dynamic Pharmaceutical/Biotech Sector Marks Depositary Receipt Activity in First Half of 2015, says BNY Mellon

- Bio-pharma firms account for 67% of all DR capital raising transactions and 34% of total DR capital raised through June

NEW YORK

Lilly Provides Update on Evacetrapib Phase 3 Trial

INDIANAPOLIS, July 27, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has accepted the recommendation

Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit

HERTFORDSHIRE, England and PITTSBURGH, July 27, 2015 /PRNewswire/ -- My

Allergan Accelerates Transformation to Branded Growth Pharma Leader by Divesting Global Generics Business to Teva for $40.5 Billion

DUBLIN, July 27, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it has entered into a definitive agreement under which Teva Pharmaceutical Industries Ltd. will acquire...

FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma

Approval Expands Kyprolis Indication Patients Treated With Kyprolis in Combination With Standard of Care Lived 50 Percent Longer Without Disease Worsening Compared to Standard of Care Alone in...

Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit

HERTFORDSHIRE, England and PITTSBURGH, July 27, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today issued the following statement regarding Teva's (NYSE and TASE: TEVA) announcement of its entry...

Teva to Acquire Allergan Generics for $40.5 Billion Creating a Transformative Generics and Specialty Company Well Positioned to Win in Global Healthcare

Acquisition Strongly Reinforces Teva's Strategy, Accelerates the Creation of Its New Business Model and Opens a New Set of Possibilities for the Company In Generics and Specialty Opportunity to...

Aegerion Pharmaceuticals Announces Leadership Changes to Support the Next Stage of Growth

Aegerion Pharmaceuticals Announces Leadership Changes to Support the Next Stage of Growth Company Reports Preliminary Second Quarter 2015 Total Net Product Sales of Between $63 and $64 Million and...

AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa

AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa Monday, 27 July 2015 AstraZeneca today announced that it has entered into a definitive agreement...

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Critical Milestone for Patients With Uncontrolled Cholesterol who Require Additional Intensive LDL-C Reduction

THOUSAND OAKS, Calif.

FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma

Approval Expands Kyprolis Indication

THOUSAND OAKS, Calif., July 24, 2015 /PRNewswire/ -- Amgen

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

TARRYTOWN, N.Y. and PARIS, July 24, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicine Agency's (EMA's) Committee for...

Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones

CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for full...

ABBVIE REPORTS SECOND-QUARTER 2015 FINANCIAL RESULTS

- REPORTS SECOND-QUARTER ADJUSTED EPS OF $1.08, UP 31.7 PERCENT AND EXCEEDING PREVIOUS GUIDANCE RANGE OF $1.04 TO $1.06 (REPORTS GAAP EPS OF $0.83) - DELIVERS SECOND-QUARTER REVENUE OF $5.475...

Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2015 results, including revenues of $2.6 billion, a 7% increase compared to the second quarter of 2014....

GSK's malaria candidate vaccine, Mosquirix™ (RTS,S), receives positive opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa

24 July 2015 Issued: London, UK WHO will now assess how the world's first malaria candidate vaccine might be used alongside other tools to prevent malaria GSK announced today that the...